SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells

Biochemical Pharmacology

Volumn 64, Issue 7, 2002, Pages 1091-1100

  Yu, Bo ^a,b   Lane, Maureen E ^a,b   Wadler, Scott ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cyclin; Cyclin dependent kinase; Cyclin dependent kinase inhibitor; E2F; Retinoblastoma protein

Indexed keywords

2,6 DIAMINO 4 CYCLOHEXYLMETHOXY 5 NITROSOPYRIMIDINE; 2,6 DIAMINO O4 CYCLOHEXYLMETHYLOXY 5 NITROSOPYRIMIDINE; 3 [1 (3H IMIDAZOL 4 YL)METHYLIDENE] 5 METHOXY 1,3 DIHYDROINDOL 2 ONE; 6 O CYCLOHEXYLMETHYLGUANINE; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; FLAVOPIRIDOL; O6 CYCLOHEXYLMETHYLGUANINE; PROTEIN; PROTEIN DP 1; PROTEIN P107; PROTEIN P130; RETINOBLASTOMA PROTEIN; SU 9516; TRANSCRIPTION FACTOR E2F; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISSOCIATION; DRUG ACTIVITY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTESTINE CELL; MOLECULAR WEIGHT; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TIME;

CARRIER PROTEINS; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELLS, CULTURED; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASES; CYCLINS; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; E2F2 TRANSCRIPTION FACTOR; E2F3 TRANSCRIPTION FACTOR; E2F5 TRANSCRIPTION FACTOR; HT29 CELLS; HUMANS; IMIDAZOLES; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR WEIGHT; PROTEIN-SERINE-THREONINE KINASES; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS;

EID: 0036776132     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01264-9     Document Type: Article

References (70)

1. 1 events and regulation of cell proliferation. Science. 246:1989;603-608.
2. Sherr C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60:2000;3689-3695.
3. Nevins J.R. The Rb/E2F pathway and cancer. Hum. Mol. Genet. 10:2001;699-703.
4. Flemington E.K., Speck S.H., Kaelin W.G. E2F1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. U.S.A. 90:1993;6914-6918.
5. Zamanian M., La Thangue N.B. Transcriptional repression by the Rb-related protein p107. Mol. Biol. Cell. 4:1993;389-396.
6. Vairo G., Livingston D.M., Ginsberg D. Functional interaction between E2F4 and p130: evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members. Genes Dev. 9:1995;869-881.
7. Lees J.A., Saito M., Vidal M., Valentine M., Look T., Harlow E., Dyson N., Helin K. The retinoblastoma protein binds to a family of E2F transcription factors. Mol. Cell. Biol. 13:1993;7813-7825.
8. Sardet C., Vidal M., Cobrinik D., Geng Y., Onufryk C., Chen A., Weinberg R.A. E2F4 and E2F5, two members of the E2F family, are expressed in the early phases of the cell cycle. Proc. Natl. Acad. Sci. U.S.A. 92:1995;2403-2407.
9. Hijmans E.M., Voorhoeve P.M., Beijersbergen R.L., van't Veer L.J., Bernards R. E2F5, a new E2F family member that interacts with p130 in vivo. Mol. Cell. Biol. 15:1995;3082-3089.
10. Ginsberg D., Vairo G., Chittenden T., Xiao Z.X., Xu G., Wydner K.L., DeCaprio J.A., Lawrence J.B., Livingston D.M. E2F4, a new member of the E2F transcription factor family, interacts with p107. Genes Dev. 8:1994;2665-2679.
11. Beijersbergen R.L., Kerkhoven R.M., Zhu L., Carlée L., Voorhoeve P.M., Bernards R. E2F4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes Dev. 8:1994;2680-2690.
12. Trimarchi J.M., Fairchild B., Verona R., Moberg K., Andon N., Lees J.A. E2F6, a member of the E2F family that can behave as a transcriptional repressor. Proc. Natl. Acad. Sci. U.S.A. 95:1998;2850-2855.
13. 1. Mol. Cell. Biol. 16:1996;3698-3706.
14. Ishizaki J., Nevins J.R., Sullenger B.A. Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function. Nat. Med. 2:1996;1386-1389.
15. Leone G., DeGregori J., Yan Z., Jakoi L., Ishida S., Williams R.S., Nevins J.R. E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev. 12:1998;2120-2130.
16. Johnson D.G., Schwarz J.K., Cress W.D., Nevins J.R. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature. 365:1993;349-352.
17. Qin X.Q., Livingston D.M., Kaelin W.G. Jr. Adams PD. Deregulated transcription factor E2F1 expression leads to S phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. U.S.A. 91:1994;10918-10922.
18. Shan B., Lee W.H. Deregulated expression of E2F1 induces S phase entry and leads to apoptosis. Mol. Cell. Biol. 14:1994;8166-8173.
19. Kowalik T.F., DeGregori J., Schwarz J.K., Nevins J.R. E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis. J. Virol. 69:1995;2491-2500.
20. Dobrowolski S.F., Stacey D.W., Harter M.L., Stine J.T., Hiebert S.W. An E2F dominant negative mutant blocks E1A-induced cell cycle progression. Oncogene. 9:1994;2605-2612.
21. Gala S., Marreiros A., Stewart G.J., Williamson P. Overexpression of E2F1 leads to cytokine-independent proliferation and survival in the hematopoietic cell line BaF-B03. Blood. 97:2001;227-234.
22. Hamel P.A., Gill R.M., Phillips R.A., Gallie B.L. Transcriptional repression of the E2-containing promoters EIIaE, c-myc, and RB1 by the product of the RB1 gene. Mol. Cell. Biol. 12:1992;3431-3438.
23. Weintraub S.J., Prater C.A., Dean D.C. Retinoblastoma protein switches the E2F site from positive to negative element. Nature. 358:1992;259-261.
24. Adnane J., Shao Z., Robbins P.D. The retinoblastoma susceptibility gene product represses transcription when directly bound to the promoter. J. Biol. Chem. 270:1995;8837-8843.
25. Bremner R., Cohen B.L., Sopta M., Hamel P.A., Ingles C.J., Gallie B.L., Phillips R.A. Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol. Cell. Biol. 15:1995;3256-3265.
26. Sellers W.R., Rodgers J.W., Kaelin W.G. Jr. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc. Natl. Acad. Sci. U.S.A. 92:1995;11544-11548.
27. Luo R.X., Postigo A.A., Dean D.C. Rb interacts with histone deacetylase to repress transcription. Cell. 92:1998;463-473.
28. Cairns B.R., Kim Y.-J., Sayre M.H., Laurent B.C., Kornberg R.D. A multisubunit complex containing the SWI1/ADR6, SWI2/SNF2, SWI3, SNF5, and SNF6 gene products isolated from yeast. Proc. Natl. Acad. Sci. U.S.A. 91:1994;1950-1954.
29. Kingston R.E., Bunker C.A., Imbalzano A.N. Repression and activation by multiprotein complexes that alter chromatin structure. Genes Dev. 10:1996;905-920.
30. Peterson C.L., Dingwall A., Scott M.P. Five SWI/SNF gene products are components of a large multisubunit complex required for transcriptional enhancement. Proc. Natl. Acad. Sci. U.S.A. 91:1994;2905-2908.
31. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 389:1997;349-352.
32. Laherty C.D., Yang W.-M., Sun J.-M., Davie J.R., Seto E., Eisenman R.N. Histone deacetylases associated with the mSin3 corepressor mediate Mad transcriptional repression. Cell. 89:1997;349-356.
33. Nagy L., Kao H.Y., Chakravarti D., Lin R.J., Hassig C.A., Ayer D.E., Schreiber S.L., Evans R.M. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell. 89:1997;373-380.
34. Lundberg A.S., Weinberg R.A. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol. 18:1998;753-761.
35. 1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
36. Hinds P.W., Mittnacht S., Dulic V., Arnold A., Reed S.I., Weinberg R.A. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell. 70:1992;993-1006.
37. Ludlow J.W., Shon J., Pipas J.M., Livingston D.M., DeCaprio J.A. The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T. Cell. 60:1990;387-396.
38. Mihara K., Cao X.R., Yen A., Chandler S., Driscoll B., Murphree A.L., T'Ang A., Fung Y.K. Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science. 246:1989;1300-1303.
39. Johnson D.G., Ohtani K., Nevins J.R. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev. 8:1994;1514-1525.
40. Ohtani K., DeGregori J., Nevins J.R. Regulation of the cyclin E gene by transcription factor E2F1. Proc. Natl. Acad. Sci. U.S.A. 92:1995;12146-12150.
41. Lukas J., Herzinger T., Hansen K., Moroni M.C., Resnitzky D., Helin K., Reed S.I., Bartek J. Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev. 11:1997;1479-1492.
42. 1 cyclin-dependent kinase activity. Genes Dev. 9:1995;2873-2887.
43. INK4A and of hypophosphorylated retinoblastoma family proteins. EMBO J. 16:1997;5322-5333.
44. Arata Y., Fujita M., Ohtani K., Kijima S., Kato J.Y. Cdk2-dependent and -independent pathways in E2F-mediated S phase induction. J. Biol. Chem. 275:2000;6337-6345.
45. Morris L., Allen K.E., La Thangue N.B. Regulation of E2F transcription by cyclin E-cdk2 kinase mediated through p300/CBP co-activators. Nat. Cell. Biol. 2:2000;232-239.
46. Lane M.E., Yu B., Rice A., Lipson K.E., Liang C., Sun L., Tang C., McMahon G., Pestell R.G., Wadler S. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res. 61:2001;6170-6177.
47. Yu B., Lane M.E., Pestell R.G., Albanese C., Wadler S. Down-regulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein. Mol. Cell. Biol. Res. Commun. 3:2000;352-359.
48. Aslam F., Palumbo L., Augenlicht L.H., Velcich A. The Sp family of transcription factors in the regulation of the human and mouse MUC2 gene promoters. Cancer Res. 61:2001;570-576.
49. Arris C.E., Boyle F.T., Calvert A.H., Curtin N.J., Endicott J.A., Garman E.F., Gibson A.E., Golding B.T., Grant S., Griffin R.J., Jewsbury P., Johnson L.N., Lawrie A.M., Newell D.R., Noble M.E., Sausville E.A., Schultz R., Yu W. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem. 43:2000;2797-2804.
50. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56:1996;2973-2978.
51. Senderowicz A.M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest. New Drugs. 17:1999;313-320.
52. Otyepka M., Krystof V., Havlicek L., Siglerova V., Strnad M., Koca J. Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. J. Med. Chem. 43:2000;2506-2513.
53. Chen Y.N., Sharma S.K., Ramsey T.M., Jiang L., Martin M.S., Baker K., Adams P.D., Bair K.W., Kaelin W.G. Jr. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. U.S.A. 96:1999;4325-4329.
54. Kato J., Matsushime H., Hiebert S.W., Ewen M.E., Sherr C.J. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev. 7:1993;331-342.
55. Lees E., Faha B., Dulic V., Reed S.I., Harlow E. Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner. Genes Dev. 6:1992;1874-1885.
56. Pagano M., Draetta G., Jansen-Durr P. Association of cdk2 kinase with the transcription factor E2F during S phase. Science. 255:1992;1144-1147.
57. De Luca A., MacLachlan T.K., Bagella L., Dean C., Howard C.M., Claudio P.P., Baldi A., Khalili K., Giordano A. A unique domain of pRb2/p130 acts as an inhibitor of cdk2 kinase activity. J. Biol. Chem. 272:1997;20971-20974.
58. INK4A(+) tumor cells. J. Biol. Chem. 275:2000;30317-30325.
59. NPAT by cyclin E/cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev. 14:2000;2298-2313.
60. Muller D., Thieke K., Burgin A., Dickmanns A., Eilers M. Cyclin E-mediated elimination of p27 requires its interaction with the nuclear pore-associated protein mNPAP60. EMBO J. 19:2000;2168-2180.
61. Hua X.H., Yan H., Newport J. A role for cdk2 kinase in negatively regulating DNA replication during S phase of the cell cycle. J. Cell. Biol. 137:1997;183-192.
62. Matsumoto Y., Hayashi K., Nishida E. Cyclin-dependent kinase 2 (cdk2) is required for centrosome duplication in mammalian cells. Curr. Biol. 9:1999;429-432.
63. Keller C., Krude T. Requirement of cyclin/cdk2 and protein phosphatase 1 activity for chromatin assembly factor 1-dependent chromatin assembly during DNA synthesis. J. Biol. Chem. 275:2000;35512-35521.
64. Kitagawa M., Higashi H., Suzuki-Takahashi I., Segawa K., Hanks S.K., Taya Y., Nishimura S., Okuyama A. Phosphorylation of E2F1 by cyclin A-cdk2. Oncogene. 10:1995;229-236.
65. Xu M., Sheppard K.-A., Peng C.-Y., Yee A.S., Piwnica-Worms H. Cyclin A/CDK2 binds directly to E2F1 and inhibits the DNA-binding activity of E2F1/DP-1 by phosphorylation. Mol. Cell. Biol. 14:1994;8420-8431.
66. Krek W., Xu G., Livingston D.M. Cyclin A-kinase regulation of E2F1 DNA binding function underlies suppression of an S phase checkpoint. Cell. 83:1995;1149-1158.
67. Humbert P.O., Verona R., Trimarchi J.M., Rogers C., Dandapani S., Lees J.A. E2F3 is critical for normal cellular proliferation. Genes Dev. 14:2000;690-703.
68. Li W., Fan J., Bertino J.R. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res. 61:2001;2579-2582.
69. Dreyer M.K., Borcherding D.R., Dumont J.A., Peet N.P., Tsay J.T., Wright P.S., Bitonti A.J., Shen J., Kim S.H. Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717. J. Med. Chem. 44:2001;524-530.
70. Sielecki T.M., Boylan J.F., Benfield P.A., Trainor G.L. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem. 43:2000;1-18.